The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model

[1]  W. Phillips,et al.  Combined MEK and Pi3′-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo , 2017, Oncotarget.

[2]  J. Pouysségur,et al.  Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth. , 2016, Cancer research.

[3]  T. Oyama,et al.  Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[4]  Qian Wang,et al.  L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia. , 2015, American journal of cancer research.

[5]  J. Copland,et al.  Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target. , 2015, The Journal of clinical endocrinology and metabolism.

[6]  Thijs J. Hagenbeek,et al.  L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia , 2014, Leukemia.

[7]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.

[8]  K. Suksen,et al.  Downregulation of LAT1 expression suppresses cholangiocarcinoma cell invasion and migration. , 2014, Cellular signalling.

[9]  P. Rosário,et al.  Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence. , 2014, Thyroid : official journal of the American Thyroid Association.

[10]  M. McMahon,et al.  Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis , 2014, Molecular Cancer Research.

[11]  T. Oyama,et al.  Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer , 2014, British Journal of Cancer.

[12]  N. Anzai,et al.  Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma , 2013, BMC Cancer.

[13]  M. Gleave,et al.  Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. , 2013, Journal of the National Cancer Institute.

[14]  Wenping Luo,et al.  Downregulation of L-type amino acid transporter 1 expression inhibits the growth, migration and invasion of gastric cancer cells , 2013, Oncology letters.

[15]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[16]  P. Massion,et al.  SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival , 2012, Clinical Cancer Research.

[17]  Y. Nikiforov,et al.  American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. , 2012, Thyroid : official journal of the American Thyroid Association.

[18]  V. Detours,et al.  A general method to derive robust organ-specific gene expression-based differentiation indices: application to thyroid cancer diagnostic , 2012, Oncogene.

[19]  H. Endou,et al.  c-Myc is crucial for the expression of LAT1 in MIA Paca-2 human pancreatic cancer cells. , 2012, Oncology reports.

[20]  N. Sunaga,et al.  Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer , 2012, British Journal of Cancer.

[21]  Laura M. Heiser,et al.  A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. , 2012, Cancer discovery.

[22]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[23]  Kylie L. Gorringe,et al.  An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. , 2012, The Journal of clinical investigation.

[24]  J. Horiguchi,et al.  Correlation of L‐type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis , 2012, Cancer science.

[25]  S. Larson,et al.  Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. , 2011, The Journal of clinical investigation.

[26]  Qian Wang,et al.  Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. , 2011, Cancer research.

[27]  Takashi Ishikawa,et al.  Plasma Free Amino Acid Profiling of Five Types of Cancer Patients and Its Application for Early Detection , 2011, PloS one.

[28]  M. McMahon,et al.  Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. , 2011, Cancer research.

[29]  Yoshiyuki Suzuki,et al.  High expression of L‐type amino‐acid transporter 1 (LAT1) in gastric carcinomas: Comparison with non‐cancerous lesions , 2011, Pathology international.

[30]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[31]  H. Arakawa,et al.  Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors. , 2010, Biochemical pharmacology.

[32]  Y. Kanai,et al.  l‐Type amino acid transporter 1 inhibitors inhibit tumor cell growth , 2010, Cancer science.

[33]  R. DePinho,et al.  BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.

[34]  Jeffrey P. MacKeigan,et al.  Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy , 2009, Cell.

[35]  Y. Kanai,et al.  L‐type amino‐acid transporter 1 as a novel biomarker for high‐grade malignancy in prostate cancer , 2009, Pathology international.

[36]  N. Sunaga,et al.  l‐type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms , 2008, Cancer science.

[37]  H. Iijima,et al.  Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. , 2008, Pathology, research and practice.

[38]  M. Serrano,et al.  A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. , 2007, Genes & development.

[39]  Shigeru Takahashi,et al.  Amino acid limitation induces expression of ATF5 mRNA at the post-transcriptional level. , 2007, Life sciences.

[40]  Louise Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.

[41]  M. Santoro,et al.  Mutation of the PIK3CA gene in anaplastic thyroid cancer. , 2005, Cancer research.

[42]  M. Xing,et al.  BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.

[43]  엔도 히토시,et al.  Aromatic amino acid derivatives and medicinal compositions , 2003 .

[44]  E. Babu,et al.  Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. , 2002, Biochimica et biophysica acta.

[45]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[46]  J. Ritchie,et al.  Role of the System L permease LAT1 in amino acid and iodothyronine transport in placenta. , 2001, The Biochemical journal.

[47]  Bradley E. Enerson,et al.  Expression of Large Amino Acid Transporter LAT1 in Rat Brain Endothelium , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[48]  I. Fleming,et al.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995 , 1998, Cancer.

[49]  C. Shoemaker,et al.  Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family , 1998, Nature.

[50]  Eiji Takeda,et al.  Expression Cloning and Characterization of a Transporter for Large Neutral Amino Acids Activated by the Heavy Chain of 4F2 Antigen (CD98)* , 1998, The Journal of Biological Chemistry.

[51]  M. Ranney,et al.  Beyond the bedside: Clinicians as guardians of public health, medicine and science , 2020, The American Journal of Emergency Medicine.

[52]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[53]  M. Schott,et al.  Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult Mouse , 2012 .

[54]  E. Mazzaferri,et al.  Increasing Incidence of Thyroid Cancer in the United States, 1973–2002Davies L, Welch HG (Dept of Veterans Affairs Med Ctr, White River Junction, Vt; Darmouth Med School, Hanover, NH) JAMA 295:2164–2167, 2006§ , 2007 .

[55]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.